HK1248601A1 - 作為激酶抑制劑的嘧啶衍生物及其治療應用 - Google Patents
作為激酶抑制劑的嘧啶衍生物及其治療應用Info
- Publication number
- HK1248601A1 HK1248601A1 HK18108612.1A HK18108612A HK1248601A1 HK 1248601 A1 HK1248601 A1 HK 1248601A1 HK 18108612 A HK18108612 A HK 18108612A HK 1248601 A1 HK1248601 A1 HK 1248601A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kinase inhibitors
- pyrimidine derivatives
- therapeutical applications
- therapeutical
- applications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2015/018085 WO2016137506A1 (en) | 2015-02-27 | 2015-02-27 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1248601A1 true HK1248601A1 (zh) | 2018-10-19 |
Family
ID=56789187
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18108611.2A HK1248600B (zh) | 2015-02-27 | 2018-07-03 | 作為激酶抑制劑的嘧啶衍生物及其治療應用 |
HK18108612.1A HK1248601A1 (zh) | 2015-02-27 | 2018-07-03 | 作為激酶抑制劑的嘧啶衍生物及其治療應用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18108611.2A HK1248600B (zh) | 2015-02-27 | 2018-07-03 | 作為激酶抑制劑的嘧啶衍生物及其治療應用 |
Country Status (13)
Country | Link |
---|---|
US (2) | US10766879B2 (zh) |
EP (2) | EP3261637B1 (zh) |
JP (2) | JP6444525B2 (zh) |
KR (2) | KR20170122782A (zh) |
CN (2) | CN107708690B (zh) |
AU (2) | AU2015383881B2 (zh) |
BR (2) | BR112017018183A2 (zh) |
CA (2) | CA2977764C (zh) |
ES (1) | ES2746007T3 (zh) |
HK (2) | HK1248600B (zh) |
IL (2) | IL254152B (zh) |
RU (2) | RU2701188C2 (zh) |
WO (2) | WO2016137506A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2977764C (en) * | 2015-02-27 | 2021-11-09 | Nantbioscience, Inc. | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications |
CN108530361A (zh) * | 2018-05-17 | 2018-09-14 | 重庆医药高等专科学校 | 一种5-[2-(3,5-二甲氧基苯基)乙基]-1h-吡唑-3-胺的合成工艺 |
CN113354599B (zh) * | 2021-08-09 | 2021-10-26 | 长沙康鹏医药有限公司 | 尼达尼布关键中间体的制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
EP2270006A1 (en) * | 2002-08-08 | 2011-01-05 | Amgen, Inc | Pyridazine derivatives useful as vanilloid receptor ligands |
CA2488739A1 (en) * | 2002-08-30 | 2004-03-11 | Eisai Co., Ltd. | Nitrogen-containing aromatic derivatives |
US8013153B2 (en) * | 2006-03-23 | 2011-09-06 | Janssen Pharmaceutica, N.V. | Substituted pyrimidine kinase inhibitors |
WO2008128231A1 (en) * | 2007-04-16 | 2008-10-23 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
UY32351A (es) * | 2008-12-22 | 2010-07-30 | Astrazeneca Ab | Compuestos de pirimidinil indol para uso como inhibidores de atr |
EP2451811A1 (en) | 2009-05-27 | 2012-05-16 | F. Hoffmann-La Roche AG | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
SG181961A1 (en) * | 2009-12-25 | 2012-08-30 | Mochida Pharm Co Ltd | Novel 3-hydroxy-5-arylisothiazole derivative |
WO2014071378A1 (en) * | 2012-11-05 | 2014-05-08 | Nant Holdings Ip, Llc | Substituted indol-5-ol derivatives and their therapeutical applications |
CN105377261B (zh) * | 2013-03-15 | 2017-12-15 | 南特生物科学公司 | 取代的吲哚‑5‑酚衍生物和它们的治疗应用 |
WO2014183300A1 (en) * | 2013-05-17 | 2014-11-20 | Suzhou Vivotide Biotechnologies Co., Ltd. | Vegfr tyrosine kinase inhibitors |
CA2977764C (en) | 2015-02-27 | 2021-11-09 | Nantbioscience, Inc. | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications |
-
2015
- 2015-02-27 CA CA2977764A patent/CA2977764C/en active Active
- 2015-02-27 CN CN201580078344.7A patent/CN107708690B/zh active Active
- 2015-02-27 JP JP2017545365A patent/JP6444525B2/ja active Active
- 2015-02-27 RU RU2017133419A patent/RU2701188C2/ru active
- 2015-02-27 US US15/553,890 patent/US10766879B2/en active Active
- 2015-02-27 KR KR1020177026941A patent/KR20170122782A/ko not_active Application Discontinuation
- 2015-02-27 AU AU2015383881A patent/AU2015383881B2/en active Active
- 2015-02-27 WO PCT/US2015/018085 patent/WO2016137506A1/en active Application Filing
- 2015-02-27 BR BR112017018183A patent/BR112017018183A2/pt active Search and Examination
- 2015-02-27 EP EP15883597.5A patent/EP3261637B1/en active Active
-
2016
- 2016-02-29 ES ES16756548T patent/ES2746007T3/es active Active
- 2016-02-29 CN CN201680018774.4A patent/CN107635553B/zh active Active
- 2016-02-29 JP JP2017545369A patent/JP6442071B2/ja active Active
- 2016-02-29 RU RU2017133448A patent/RU2718915C2/ru not_active IP Right Cessation
- 2016-02-29 CA CA2977810A patent/CA2977810A1/en not_active Abandoned
- 2016-02-29 KR KR1020177026878A patent/KR102008082B1/ko active IP Right Grant
- 2016-02-29 WO PCT/US2016/020095 patent/WO2016138527A1/en active Application Filing
- 2016-02-29 BR BR112017018409A patent/BR112017018409A2/pt not_active Application Discontinuation
- 2016-02-29 US US15/553,870 patent/US20180215734A1/en not_active Abandoned
- 2016-02-29 AU AU2016224969A patent/AU2016224969B2/en active Active
- 2016-02-29 EP EP16756548.0A patent/EP3261638B1/en active Active
-
2017
- 2017-08-24 IL IL254152A patent/IL254152B/en active IP Right Grant
- 2017-08-24 IL IL254151A patent/IL254151A0/en active IP Right Grant
-
2018
- 2018-07-03 HK HK18108611.2A patent/HK1248600B/zh unknown
- 2018-07-03 HK HK18108612.1A patent/HK1248601A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256535A1 (zh) | 吡唑嘧啶衍生物及其用途 | |
IL268614B (en) | Aminotriazolopyridines as kinase inhibitors | |
AP2016009487A0 (en) | Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors | |
IL259150B (en) | Pyrimidine derivative and use thereof | |
SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
ZA201708568B (en) | Pyrimidine derivatives as btk inhibitors and uses thereof | |
IL274207B (en) | Aminoimidazopyridazines as kinase inhibitors | |
HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
HK1248601A1 (zh) | 作為激酶抑制劑的嘧啶衍生物及其治療應用 | |
EP3284746A4 (en) | Preparation and use of kinase inhibitor | |
IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
EP3347357A4 (en) | HETEROCYCLIC KINASEINHIBITORS OF THE TEC FAMILY | |
GB201705201D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201609580D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201505460D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201519382D0 (en) | Kinase inhibitors | |
GB201519381D0 (en) | Kinase inhibitors | |
GB201514761D0 (en) | Preparation and uses of pyrimidinone derivatives |